Citi Calls Olema Drop After AstraZeneca Trial Miss a Buying Opportunity
Citi calls Olema’s drop after AstraZeneca’s SERENA-4 miss excessive, keeps Buy and $59 target, and sees $20 value from later-line use.
/ 23 items
#AZN↓
AstraZeneca’s Etcamah Combination Falls Short of Statistical Significance in SERENA-4
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Ionis-AstraZeneca Heart Trial Fails; Analysts See Neutral-to-Negative Read-Through for Alnylam
Eplontersen failed to reduce heart events in 1,432 ATTR-CM patients. Results raise questions on silencer-plus-stabilizer use and for Alnylam’s pipeline.
AstraZeneca Shares Rebound After Bristol Myers Deal Rumors Quashed
Senior source tells Reuters there are no talks between AstraZeneca and Bristol Myers Squibb, ending $400B merger rumors and lifting shares.
AstraZeneca and Bristol Myers Squibb Explore $400 Billion Pharma Merger
Cancer drugs drive sales for both, with direct overlaps like Imfinzi and Opdivo raising antitrust risks.
H.C. Wainwright Reiterates Buy on Omeros After AstraZeneca’s Ultomiris Phase 3 Miss
AstraZeneca’s Ultomiris Phase 3 miss in adult HSCT-TMA is a clear positive for Omeros’ Yartemlea, removing a key rival.